[6-(2-PHENYLETHYL)-2-OXO-2H-PYRAN-4-YL]DIPHENYLPHOSPHINOTHIONATE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	WCDBIHMXGQMYPF-UHFFFAOYSA-N
Smiles	O=C1OC(=CC(=C1)OP(=S)(Oc2ccccc2)Oc3ccccc3)CCc4ccccc4
InChI	InChI=1S/C25H21O5PS/c26-25-19-24(18-23(27-25)17-16-20-10-4-1-5-11-20)30-31(32,28-21-12-6-2-7-13-21)29-22-14-8-3-9-15-22/h1-15,18-19H,16-17H2

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C25H21O5PS
Molecular Weight	464.47
AlogP	6.37
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	9.0
Polar Surface Area	95.89
Molecular species	None
Aromatic Rings	3.0
Heavy Atoms	32.0

Assay Description	Organism	Bioactivity
Antifungal activity against Athelia rolfsii assessed as growth inhibition at 1000 ppm by agar dilution method relative to control	Athelia rolfsii	29.0 %
Antifungal activity against Pythium sp. assessed as growth inhibition at 1000 ppm by agar dilution method relative to control	Pythium	3.0 %
Antifungal activity against Athelia rolfsii assessed as growth inhibition at 100 ppm by agar dilution method relative to control	Athelia rolfsii	17.0 %
Antifungal activity against Pythium sp. assessed as growth inhibition at 100 ppm by agar dilution method relative to control	Pythium	0.0 %
Insecticidal activity against Coptotermes formosanus assessed as increase in mortality at 1 mg/filter paper measured for 14 days relative to control	Coptotermes formosanus	None

Cross References

Resources	Reference
ChEMBL	CHEMBL2268834
PubChem	76323181

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).